Head-to-head evidence
Ebronucimab vs Recaticimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Developed by Akeso
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. However, its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome, and the registry does not report whether the comparison was favorable or statistically significant.
Recaticimab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04849000 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Recaticimab's landscape